Overview
February 28, 2009
Atlanta,GA
Program Director: Chandra P. Belani, MD, Miriam Beckner Distinguished Professor of Medicine, Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Deputy Director, Penn State Cancer Institute, Hershey, PA
February 28 , 2009,
JW Marriott Buckhead Atlanta,
3300 Lenox Road,
Atlanta,
GA 30326 ,
Phone (404) 262-3344
Jointly sponsored by International Cancer Network and Postgraduate Institute for Medicine
Educational Grants
This activity is supported by educational grants from:
Eli Lilly Oncology
Bristol-Myers Squibb Company/
Imclone Systems Incorporated
Genentech BioOncology
Bayer Healthcare Pharmaceuticals/
Onyx
Target Audience
This symposium is directed primarily to medical oncologists, radiation oncologists, surgical oncologists, pharmacists, and registered oncology nurses interested in new developments for treatment of lung cancer. No specific skill or knowledge other than a basic training in oncology is required for successful participation in this activity. Fellows are also invited to attend.
Statement of Need/Program Overview
This program is intended to facilitate interaction among oncologists and nurses interested in development of novel therapeutics for treatment of lung cancer. In addition to multimodality therapy, adjuvant therapy, this symposium will present data of most promising emerging agents currently in development for the treatment of lung cancer. There will be in-depth discussion of both antiangiogenic agents and inhibitors of EGFR pathways. Drugs that target multiple signaling pathways will also be given significant focus.
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the current status of chemotherapy, radiation therapy, and state-of-the-art therapies of lung cancer
- Define the current status of radiation therapy and multimodality therapy in the treatment of localized and advance lung cancer
- Outline the clinical data supporting the use of EGFR inhibitors in the treatment of lung cancer
- Review agents that target angiogenesis, including the safety profile and efficacy
- Specify the impact of multi-targeted kinase inhibitors in the management of lung cancer
- Describe novel therapeutic agents that potentially improve upon standard chemotherapeutics
Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and International Cancer Network. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Postgraduate Institute for Medicine designates this educational activity for a maximum of 5.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity
Nursing Accreditation Statements
purpose
The purpose of this educational meeting is to assist healthcare providers develop appropriate treatment strategies that minimize side effects and optimize outcomes in patients with lung cancer.
Accreditation Statements
CNA/ANCC
This educational activity for 5.5 contact hours is provided by Postgraduate Institute for Medicine (PIM).
PIM is an approved provider of continuing nursing education by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Pharmacist Continuing Education
Accreditation Statement
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credit Designation
Postgraduate Institute for Medicine designates each session of this continuing education activity for 1.8 contact hour(s) (0.18 CEUs) of the Accreditation Council for Pharmacy Education. (Session I Universal Program Number 809-999-09-001-L01-P; Session II Universal Program Number 809-999-09-002-L01-P; Session III Universal Program Number 809-999-09-003-L01-P)
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Roberta Granny prior to the live event at 410-491-7492.